Response to: "Renal biopsies should be performed whenever treatment strategies depend on renal involvement"

M Yates, DR Jayne, C Mukhtyar

Research output: Contribution to journalLetter

1 Citation (Scopus)
8 Downloads (Pure)


We thank Chemouny et al for their letter and concur with their conclusions. As we state (1): “A positive biopsy for AAV is helpful when considering an initial diagnosis or recurrent disease.” In our view, renal biopsy is important to establish diagnosis and may also provide an indication of prognostic trajectory and although existing classification systems need further validation, changes like glomerular sclerosis have obvious adverse prognostic value for patients with AAV (2-4). The Delphi process, for the scope of the current recommendations, identified the role of biopsy at both diagnosis and follow-up as an important item for update. Histopathological evidence of vasculitis, such as pauci-immune glomerulonephritis or necrotising vasculitis in any organ, remains the gold standard for diagnostic purposes. The likely diagnostic yield varies and is dependent on the organ targeted and in patients with GPA with renal involvement can be as high as 91.5% from renal biopsy (5). As Chemouny and colleagues have demonstrated, a renal biopsy was definitive in determining their management decisions. However during follow-up when relapses occur, it may be prudent to consider judicious use of further kidney biopsy during suspected renal relapse since the cause for acute kidney injury may be due to another cause other than AAV (6).
Kind regards,
M Yates, C Mukhtyar and DR Jayne on behalf of co-authors.
Original languageEnglish
Article numbere28
JournalAnnals of the Rheumatic Diseases
Early online date25 Jan 2017
Publication statusPublished - 1 Aug 2017

Cite this